Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation

J Bone Miner Metab. 2010 May;28(3):276-88. doi: 10.1007/s00774-009-0134-y. Epub 2009 Nov 19.

Abstract

Human bone marrow mesenchymal stem cells (MSCs) are pleiotrophic cells that differentiate to either adipocytes or osteoblasts as a result of crosstalk by specific signaling pathways including heme oxygenase (HO)-1/-2 expression. We examined the effect of inducers of HO-1 expression and inhibitors of HO activity on MSC differentiation to the osteoblast and following high glucose exposure. MSC cultured in osteogenic medium increased expression of osteonectin, Runt-related transcription factor 2 (RUNX-2), osteocalcin, and alkaline phosphatase. HO-1 expression during differentiation was initially decreased and then followed by a rebound increase after 15 days of culture. Additionally, the effect of HO-1 on osteoblasts appears different to that seen in adipocyte stem cells. On addition of a cobalt compound, the resultant induction of HO-1 decreases adipogenesis. Moreover, glucose (30 mM) inhibited osteoblast differentiation, as evidenced by decreased bone morphogenetic protein (BMP)-2, osteonectin, osteocalcin, and osteoprotegerin (OPG). In contrast, MSC-derived adipocytes were increased by glucose. Increased HO-1 expression increased the levels of osteonectin, OPG, and BMP-2. Inhibition of HO activity prevented the increase in osteonectin and potentiated the decrease of osteocalcin and OPG in cells exposed to high glucose levels. Furthermore, targeting HO-1 expression increased pAMPK and endothelial nitric oxide synthase (eNOS) and restored osteoblastic markers. Our findings suggest that targeting HO-1 gene expression attenuates the hyperglycemia-mediated decrease in MSC-derived osteoblast differentiation. Finally, the mechanism underlying the HO-1-specific cell effect on osteoblasts and adipocytes is yet to be explored. Thus, the targeting of HO-1 gene expression presents a portal to increase osteoblast function and differentiation and attenuate osteoporosis by promoting bone formation.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Adipogenesis / drug effects
  • Biomarkers / metabolism
  • Bone Diseases, Metabolic / etiology
  • Bone Diseases, Metabolic / prevention & control
  • Cell Differentiation* / drug effects
  • Cells, Cultured
  • Diabetes Mellitus, Type 2 / complications
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Gene Expression Regulation, Enzymologic* / drug effects
  • Heme Oxygenase-1 / antagonists & inhibitors
  • Heme Oxygenase-1 / genetics
  • Heme Oxygenase-1 / metabolism*
  • Humans
  • Hyperglycemia / physiopathology
  • Mesenchymal Stem Cells / cytology*
  • Mesenchymal Stem Cells / enzymology*
  • Nitric Oxide Synthase Type III / metabolism
  • Osteoblasts / cytology*
  • Osteoblasts / enzymology*
  • Osteocalcin / genetics
  • Osteocalcin / metabolism
  • Osteogenesis / drug effects
  • Osteoporosis / etiology
  • Osteoporosis / prevention & control
  • Osteoprotegerin / genetics
  • Osteoprotegerin / metabolism
  • RNA, Messenger / metabolism
  • Time Factors

Substances

  • Biomarkers
  • Enzyme Inhibitors
  • Osteoprotegerin
  • RNA, Messenger
  • TNFRSF11B protein, human
  • Osteocalcin
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III
  • HMOX1 protein, human
  • Heme Oxygenase-1
  • AMP-Activated Protein Kinases